XML 300 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]    
Total revenues $ 300.4 $ 164.3
Operating expenses:    
Cost of goods and services sold 144.6 152.9
Research and development 15.1 40.7
Selling, general and administrative 84.7 101.3
Amortization of intangible assets 16.2 17.0
Total operating expenses 260.6 311.9
Income (loss) from operations 39.8 (147.6)
Other income (expense):    
Interest expense (24.3) (17.9)
Other, net (3.4) 4.9
Total other income (expense), net (27.7) (13.0)
Income (loss) before income taxes 12.1 (160.6)
Income tax provision 3.1 25.6
Net income (loss) $ 9.0 $ (186.2)
Earnings Per Share, Diluted [Abstract]    
Basic (in dollars per share) $ 0.17 $ (3.71)
Diluted (in dollars per share) $ 0.17 $ (3.71)
Weighted average shares outstanding    
Basic (in shares) 52.2 50.2
Diluted (in shares) 52.2 50.2
Total Product sales, net    
Revenues [Abstract]    
Product sales $ 273.9 $ 143.4
Commercial Product sales    
Revenues [Abstract]    
Product sales 118.5 106.2
Operating expenses:    
Cost of goods and services sold 52.1 45.8
MCM Product sales    
Revenues [Abstract]    
Product sales 155.4 37.2
Operating expenses:    
Cost of goods and services sold 62.2 55.4
Total Bioservices revenues    
Revenues [Abstract]    
Total Bioservices revenues 18.5 14.4
Operating expenses:    
Cost of goods and services sold 30.3 51.7
Services    
Revenues [Abstract]    
Product sales 18.3 12.6
Leases    
Revenues [Abstract]    
Leases 0.2 1.8
Contracts and grants    
Revenues [Abstract]    
Product sales $ 8.0 $ 6.5